{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:33:00Z","timestamp":1790656380407,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1023\/a:1006325929424","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T20:36:27Z","timestamp":1040502987000},"page":"139-148","source":"Crossref","is-referenced-by-count":32,"title":["Cytotoxic Effects of Topotecan Combined with Various Active G2\/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines"],"prefix":"10.1007","volume":"18","author":[{"given":"Miquel","family":"Taron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Plasencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"260337_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bjc.1996.362","volume":"74","author":"J Dancey","year":"1996","unstructured":"Dancey J, Eisenhauer E: Current perspectives on camptothecins in cancer treatment (Editorial). Br J Cancer 74: 327\u2013338, 1996","journal-title":"Br J Cancer"},{"issue":"4","key":"260337_CR2","first-page":"221","volume":"85","author":"RC Donehower","year":"1993","unstructured":"Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumour agents. J Natl Cancer Inst 85(4): 221\u2013291, 1993","journal-title":"J Natl Cancer Inst"},{"key":"260337_CR3","first-page":"2643","volume":"32","author":"LH Li","year":"1972","unstructured":"Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643\u20132650, 1972","journal-title":"Cancer Res"},{"issue":"2","key":"260337_CR4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/bjc.1997.364","volume":"76","author":"E Johnson","year":"1997","unstructured":"Johnson E, Fridborg H, Cs\u00f3ka K, Sundstrom C, Nygren P, Larsson R: Cytotoxic activity of Topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76(2): 211\u2013219, 1997","journal-title":"Br J Cancer"},{"key":"260337_CR5","first-page":"6365","volume":"49","author":"E Holm","year":"1989","unstructured":"Holm E, Lovey JM, Kerrigan D, Pomier Y: Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and 11 in Chinese hamster DC3F cells. Cancer Res 49: 6365\u20136368, 1989","journal-title":"Cancer Res"},{"key":"260337_CR6","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/84.23.1816","volume":"84","author":"HA Burris","year":"1992","unstructured":"Burris HA, Hanauske, A, Johnson F, Marshall M, Khun J, Hilsenbeck SE, Von Hoff DD: Activity of topotecan, a new topoisomerase I inhibitor against human colony-forming units in vitro. J Natl Cancer Inst 84: 1816\u20131819, 1992","journal-title":"J Natl Cancer Inst"},{"key":"260337_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.1996.14.2.503","volume":"14","author":"R Perez-Soler","year":"1996","unstructured":"Perez-Soler R, Fosella F, Glisson B, Lee J, Murphy W, Shin D, Kemp BL, Lee JJ, Kave J, Robinson RA, Lippman SM, Kurie JM, Huber W, Raber MN, Hong WK: Phase 11 study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503\u2013513, 1996","journal-title":"J Clin Oncol"},{"key":"260337_CR8","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V85.10.2817.bloodjournal85102817","volume":"85","author":"FM Uckun","year":"1995","unstructured":"Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J, Evans WE: In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85: 2817\u2013282, 1995","journal-title":"Blood"},{"key":"260337_CR9","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","volume":"14","author":"GJ Creemers","year":"1996","unstructured":"Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R: Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of large European phase H study. J Clin Oncol 14: 3056\u20133061, 1996","journal-title":"J Clin Oncol"},{"key":"260337_CR10","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","volume":"260","author":"YH Hsiang","year":"1985","unstructured":"Hsiang YH, Hertzberg F, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1. J Biol Chem 260: 14873\u201314878, 1985","journal-title":"J Biol Chem"},{"issue":"11","key":"260337_CR11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jnci\/88.11.734","volume":"88","author":"S Kaufmann","year":"1996","unstructured":"Kaufmann S, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK: Cytotoxic, effects of Topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88 (11): 734\u2013741, 1996","journal-title":"J Natl Cancer Inst"},{"key":"260337_CR12","first-page":"5077","volume":"49","author":"YK Hsiang","year":"1989","unstructured":"Hsiang YK, Lihon MG, Liu LF: Arrest of replication forks by drug-stabilized Topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077\u20135082, 1989","journal-title":"Cancer Res"},{"key":"260337_CR13","first-page":"6919","volume":"50","author":"P D'Arpa","year":"1990","unstructured":"D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of Topoisomerase Poisons. Cancer Res 50: 6919\u20136924, 1990","journal-title":"Cancer Res"},{"key":"260337_CR14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1073\/pnas.73.10.3488","volume":"73","author":"J Champoux","year":"1976","unstructured":"Champoux J: Evidence for a intermediate with a single-strand break in the reaction catalysed by DNA untwisting enzyme. Proc Natl Acad Sci (USA) 73: 384\u2013391, 1976","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"260337_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199549010-00002","volume":"49","author":"BK Shinka","year":"1995","unstructured":"Shinka BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11\u201319, 1995","journal-title":"Drugs"},{"key":"260337_CR16","first-page":"4430","volume":"56","author":"F Goldwasser","year":"1996","unstructured":"Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y: Correlation between S and G2 arrest and the cytotoxicity of Camptothecin in Human Colon Carcinoma Cells. Cancer Res 56: 4430\u20134037, 1996","journal-title":"Cancer Res"},{"key":"260337_CR17","first-page":"2746","volume":"50","author":"G Del Bino","year":"1990","unstructured":"Del Bino G, Skiersky TS, Darzynkiewiz Z: Diverse effects of camptothecin an inhibitor of topoisomerase I on the cell cycle (L210, MOLT4) and myelogenous (HL60, KGI) leukemic cells. Cancer Res 50: 2746\u20132750, 1990","journal-title":"Cancer Res"},{"key":"260337_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","volume":"85","author":"WJ Slichenmeyer","year":"1993","unstructured":"Slichenmeyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as anticancer agents. J Natl Cancer Inst 85: 271\u2013287, 1993","journal-title":"J Natl Cancer Inst"},{"key":"260337_CR19","first-page":"1823","volume":"52","author":"T. Yeou-Ping","year":"1992","unstructured":"Yeou-Ping Tsao, D'Arpa P, Liu LF: The involvement of active DNA synthesis in Camptothecin-induced G2 arrest: altered 147 regulation of p34cdc2 \/ cyclin B1. Cancer Res 52: 1823\u20131829, 1992","journal-title":"Cancer Res"},{"key":"260337_CR20","first-page":"4029","volume":"57","author":"R Shao","year":"1997","unstructured":"Shao R, Cao C, Shimizu T, O'Connor PM, Kohn KW, Pomier Y: Abrogation of an S-phase checkpoint and potentiation of Camptothecin cytotoxicity by 7-Hydroxistausporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57: 4029\u20134035, 1997","journal-title":"Cancer Res"},{"key":"260337_CR21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0014-2964(78)90002-6","volume":"14","author":"B Barlogie","year":"1978","unstructured":"Barlogie B, Drewinko B: Cell cycle stage-dependent induction of G2-phase arrest by different antitumour agents. Eur J Cancer 14: 741\u2013745, 1978","journal-title":"Eur J Cancer"},{"key":"260337_CR22","first-page":"109","volume":"10","author":"N Stewart","year":"1995","unstructured":"Stewart N, I-Ecks GE, Paraskevas F, Mowat M: Evidence for a second cell cycle block at G2\/M by p53. Oncogene 10: 109\u2013115, 1995","journal-title":"Oncogene"},{"key":"260337_CR23","first-page":"818","volume":"57","author":"A Skladanowski","year":"1997","unstructured":"Skladanowski A, Larsen AK: Expression of a wild-type p53 increases Etoposide cytotoxicity in M1myeloid leukemia cells by facilited G2 to M transition: implications for gene therapy. Cancer Res 57: 818\u2013823, 1997","journal-title":"Cancer Res"},{"issue":"6","key":"260337_CR24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe SW, Ruley BE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (6): 957\u2013967, 1993","journal-title":"Cell"},{"key":"260337_CR25","first-page":"1643","volume":"55","author":"S Fan","year":"1995","unstructured":"Fan S, Smith ML, Rivet DJ, Duba D, Zahn Q, Kohn KW Fornace AJ Jr, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cis-platin and pentoxyfilline. Cancer Res 55: 1643\u20131648, 1995","journal-title":"Cancer Res"},{"key":"260337_CR26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1023\/A:1008361818480","volume":"10","author":"CG Ferreira","year":"1999","unstructured":"Ferreira CG, Tolis, C, Giaccone G. p53 and chemosensitivity. Ann Oncol 10: 1011\u20131021, 1999","journal-title":"Ann Oncol"},{"key":"260337_CR27","first-page":"81","volume":"5","author":"BI Sikic","year":"1988","unstructured":"Sikic BI: Biochemichal and cellular determination of Bleomycin cytotoxicity. Cancer Surv 5: 81\u201396, 1988","journal-title":"Cancer Surv"},{"key":"260337_CR28","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/nar\/4.10.3573","volume":"4","author":"LF Povirk","year":"1977","unstructured":"Povirk LF, W\u00fcbker W, K\u00f6hnlein W, Hutchinson F: DNA double-strand breaks and alkali-labile bonds produced by Bleomycin. Nucleic Acid Res 4: 3573\u20133580, 1977","journal-title":"Nucleic Acid Res"},{"issue":"5","key":"260337_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0006-2952(91)90394-K","volume":"42","author":"B Poddevin","year":"1991","unstructured":"Poddevin B, Orlowsky S, Belehradek J Jr, Mir LM: Very high cytotoxicity of Bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 42(5): 67\u201375, 1991","journal-title":"Biochem Pharmacol"},{"key":"260337_CR30","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/1097-0142(197412)34:6<1873::AID-CNCR2820340603>3.0.CO;2-U","volume":"34","author":"LS Desai","year":"1974","unstructured":"Desai LS, Khriskan A, Foley GE: Effects of Bleomycin on cells in culture cytochemical study. Cancer 34: 1973\u20131977, 1974","journal-title":"Cancer"},{"key":"260337_CR31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.1040790210","volume":"76","author":"RA Tobey","year":"1972","unstructured":"Tobey RA: Arrest of chinese hamster cells in G2 following treatment with the anti-tumor drug Bleomycin. J Cell Physiol 76: 259\u2013265, 1972","journal-title":"J Cell Physiol"},{"key":"260337_CR32","first-page":"105","volume-title":"Manual of Oncologic Therapeutics","author":"JL Green","year":"1995","unstructured":"Green JL, De Carvalho K Wittes RE, Allegra CJ: Chemotherapy: the properties and uses of single agents. In: MacDonald JS, Haller DG, Mayer RJ (eds): Manual of Oncologic Therapeutics. (Third edition) JB Lippincott Company, Philadelphia, 1995, pp 105\u2013106","edition":"Third edition"},{"key":"260337_CR33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00873957","volume":"12","author":"BT Hill","year":"1994","unstructured":"Hill BT, Whelan RDK Shellard SA, McClean S, Hosking LK: Differential cytotoxic effects of Docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Inv New Drugs 12: 169\u2013182, 1994","journal-title":"Inv New Drugs"},{"key":"260337_CR34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/BF00685595","volume":"30","author":"LR Kelland","year":"1992","unstructured":"Kelland LR and Abel G: Comparative \u201cin vitro\u201d cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemoth Pharmacol 30: 444\u2013450, 1992","journal-title":"Cancer Chemoth Pharmacol"},{"key":"260337_CR35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B: Placitaxel (Taxot) and Docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495\u2013505, 1994","journal-title":"Ann Oncol"},{"key":"260337_CR36","first-page":"4845","volume":"5","author":"MC Bissery","year":"1995","unstructured":"Bissery MC, Guenard D, Gueritte-Voegelein G, Lavelle F: Experimental antiturnour activity of Taxotere (RP 56976 NSC6288850), a taxol analogue. Cancer Res 5: 4845\u20134852, 1995","journal-title":"Cancer Res"},{"issue":"l","key":"260337_CR37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-291X(05)81474-3","volume":"187","author":"JF Riou","year":"1992","unstructured":"Riou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Bioch Biophys Res Com 187(l): 164\u2013170, 1992","journal-title":"Bioch Biophys Res Com"},{"key":"260337_CR38","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1021\/bi00388a037","volume":"26","author":"L Estey","year":"1987","unstructured":"Estey L, Adlakha RC, Hittleman WN, Zwelling LA: Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochem 26: 4438\u20134444, 1987","journal-title":"Biochem"},{"key":"260337_CR39","first-page":"2050","volume":"47","author":"J Markovits","year":"1987","unstructured":"Markovits J, Pomier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW: Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47: 2050\u20132055, 1987","journal-title":"Cancer Res"},{"key":"260337_CR40","first-page":"3106","volume":"45","author":"BK Long","year":"1985","unstructured":"Long BK Musial ST, Bratain MG: Single and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to Etoposide and Teniposide. Cancer Res 45: 3106\u20133112, 1985","journal-title":"Cancer Res"},{"key":"260337_CR41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/bjc.1995.9","volume":"71","author":"E. Eijdems","year":"1995","unstructured":"Eijdems EVd-IM, de Haas M, Timmerman AJ, Van der Schans GP, Kamst E, de Nooij J, Astaldi-Riccotti GCB, Borst P, Baas F: Reduced topoisomerase H activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer 71: 40\u201347, 1995","journal-title":"Br J Cancer"},{"key":"260337_CR42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02889282","volume":"24","author":"LL Vindelov","year":"1977","unstructured":"Vindelov LL: Flow microfluorometric analysis of nuclear DNA in cells from solid tumour and cell suspensions. Virchows Arch B Cell Pathol 24: 227\u2013242, 1977","journal-title":"Virchows Arch B Cell Pathol"},{"issue":"11","key":"260337_CR43","first-page":"1619","volume":"60","author":"B Drewinko","year":"1976","unstructured":"Drewinko B, Green C, Loo TL: Combination chemotherapy in vitro with cisdichloroammineplatinum (II). Cancer Treat Rep 60(11): 1619\u20131625, 1976","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"260337_CR44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/bjc.1998.571","volume":"78","author":"AC McDonald","year":"1998","unstructured":"McDonald AC, Brown R: Induction of p53-dependent and p53-independent cellular responses by topoisomerase-I inhibitors. Br J Cancer 78 (6): 745\u2013751, 1998","journal-title":"Br J Cancer"},{"key":"260337_CR45","first-page":"1","volume":"41","author":"SC Lowe","year":"1995","unstructured":"Lowe SC: Clinical implications of p53-dependent apoptosis. In Educational Book of Am Soc Clin Oncol 41: 1, 1995","journal-title":"In Educational Book of Am Soc Clin Oncol"},{"key":"260337_CR46","first-page":"6304","volume":"51","author":"MB Kastan","year":"1991","unstructured":"Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304\u20136311, 1991","journal-title":"Cancer Res"},{"key":"260337_CR47","first-page":"1129","volume":"51","author":"SH Kaufmann","year":"1991","unstructured":"Kaufmann SH: Antagonism between Camptothecin and Topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129\u20131136, 1991","journal-title":"Cancer Res"},{"key":"260337_CR48","first-page":"1425","volume":"57","author":"CM Whitacre","year":"1997","unstructured":"Whitacre CM, Zborowska. E, Gordon NH, Mackayand W, Berger NA: Topotecan increases Topoisomerase II levels and sensitivity to treatment with etoposide, in schedule-dependent processes. Cancer Res 57: 1425\u20131428, 1997","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"260337_CR49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s002800050545","volume":"39","author":"JA Bonner","year":"1996","unstructured":"Bonner JA, Kozelsky TF. The significance of the sequence administration of topotecan and etoposide: Cancer Chemother Pharmacol 39 (1\u20132): 109\u2013112, 1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"260337_CR50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0959-8049(92)90107-D","volume":"28","author":"R Bertrand","year":"1992","unstructured":"Bertrand R, O'Connor PM, Kerrigan D, Pommier Y: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT29 cells. Eur J Cancer 28: 743\u2013748, 1992","journal-title":"Eur J Cancer"},{"key":"260337_CR51","first-page":"269","volume":"6","author":"MF Cheng","year":"1994","unstructured":"Cheng MF, Chatterjee S, Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269\u2013279, 1994","journal-title":"Oncol Res"},{"issue":"1","key":"260337_CR52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","volume":"2","author":"AF Whal","year":"1996","unstructured":"Whal AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitisation to Taxol by increasing G2\/M arrest and apoptosis. Nature Med 2 (1): 72\u201379, 1996","journal-title":"Nature Med"},{"key":"260337_CR53","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/bjc.1995.232","volume":"71","author":"C Hennequin","year":"1995","unstructured":"Hennequin C, Giocanti N, Favaudon V: S-phase specificity of cell killing by Docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71: 1194\u20131198, 1995","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006325929424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006325929424\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006325929424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:17:31Z","timestamp":1753820251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006325929424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["260337"],"URL":"https:\/\/doi.org\/10.1023\/a:1006325929424","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}